Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.
Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with nonsmall cell lung cancer (NSCLC) who respond best to treatment with the PD-L1 inhibitor durvalumab.
Findings from the analysis were presented at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs. Overall, the combination of CD8+ and PD-L1+ densities correlated with response and improved overall survival with durvalumab.
Amivantamab/Lazertinib Shows OS and PFS Benefits in EGFR-Mutated NSCLC
April 21st 2025During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Read More